HIM
AQST icon

Hillsdale Investment Management’s Aquestive Therapeutics AQST Stock Holding History

Hillsdale Investment Management’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-66,600
Closed -$110K – 566
2023
Q2 		$110K Buy
+66,600
New +$120K 0.01% 369

Other funds holding AQST

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
VAFP
Vahanian & Associates Financial Planning Saratoga Springs, New York $25.3M AUM 39.42% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Corient Private Wealth
Corient Private Wealth Miami, Florida $69.9B AUM 22.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCL
Bracebridge Capital LLC Boston, Massachusetts $3.73B AUM 33.02% 1-Year Est. Return

Hillsdale Investment Management's AQST Position: Q3 2023 in Review

Hillsdale Investment Management sold out of Aquestive Therapeutics (AQST) in Q3 2023, closing a stake of 66,600 shares — an estimated $110K sold.

Hillsdale Investment Management first reported a position in AQST in Q2 2023 and held it in 1 quarter. The position peaked at $110K in Q2 2023. 47 funds tracked by Wall St. Rank hold AQST as of Q3 2023.

  • Hillsdale Investment Management reported no remaining Aquestive Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Hillsdale Investment Management sold 66,600 Aquestive Therapeutics shares in Q3 2023, an estimated $110K.
  • Hillsdale Investment Management first reported a position in Aquestive Therapeutics in Q2 2023 and held it in 1 quarter.
  • Hillsdale Investment Management's Aquestive Therapeutics position peaked at $110K in Q2 2023.
  • 47 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q3 2023.

Based on Hillsdale Investment Management's 13F filing for Q3 2023, filed 9 Nov 2023.